The latest biotech news

News and Trends 27 Jan 2023

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has identified an unexpected driver of cancer immunotherapy resistance: the harmful effect of chronic Type I Interferon signaling on tumor-killing CD8+ T cells. The findings provided new insights into the development of exhausted CD8+ T cells, which no longer effectively […]

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

Onxeo to study prostate cancer drug

French biotech company Onxeo S.A. has given an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first U.S. clinical study site, Next Oncology San Antonio. This phase 1b/2 multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients […]

January 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

FDA clearance for ‘revolutionary’ approach to J-Pouch issue

ExeGi Pharma LLC, which develops live biotherapeutic drugs and probiotics, says the FDA has cleared its Investigational New Drug (IND) application for its biologic drug candidate, EXE-346. The clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis (IPAA or J-Pouch) who experience excessive stool frequency. “Excessive stool frequency […]

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Orbsen Therapeutics happy with interim diabetic kidney disease study results

Orbsen Therapeutics Limited has announced what it says are encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for diabetic kidney disease. NEPHSTROM is a randomized, double-blind, placebo-controlled phase 1/2a, trial evaluating the safety, tolerability and preliminary efficacy of an off-the-shelf allogeneic bone marrow-derived mesenchymal stromal cell immunotherapy, ORBCEL, in adult study […]

January 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

New tool to fight antibiotic resistance

The World Health Organization (WHO) ranks antibiotic resistance as one of the top 10 threats to global health. In response, researchers at Chalmers University of Technology in Sweden have developed a new spray that can kill antibiotic-resistant bacteria, and that can be used for wound care and directly on implants and other medical devices. “Our […]

January 26, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Lupus treatment hope from Japanese miRNA research

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified two miRNAs that are downregulated in the disease and an uncommon situation that occurs in which multiple miRNAs regulate the same set of genes. Although […]

January 26, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

First patient treated in Atrogi type 2 diabetes clinical study

Atrogi AB, an early-stage Swedish pharma company, has announced that the first patient has been enrolled in a phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class novel b2 adrenoceptor agonist with a unique mechanism of action for the treatment of type 2 diabetes and comorbidities. This approach is supported by data […]

January 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Sysnav and Roche partner on movement tracking technology

Sysnav Healthcare and Roche have partnered to develop industry standard outcome measurements in diseases associated with movement impairments, as well as designing the next generation of wearable technology based on Sysnav’s technology. Patients living with a neuromuscular disorder often suffer from movement impairments that fundamentally impact their daily life. Reliable, objective measurements of a patient’s […]

January 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product

Ibex Medical Analytics has announced an agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry (IHC) scoring in breast cancer patients. Scoring of HER2 (human epidermal growth factor receptor 2) protein expression in breast […]

January 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Milestone for gene-edited therapy for sickle cell disease

Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics have announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application of exa-cel for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The submission is supported by two global phase 3 studies investigating exa-cel as a potential one-time therapy for people with […]

January 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

Alcohol-related liver disease: mechanism could lead to new therapies

Alcohol-related liver disease is among the most common causes of morbidity and mortality worldwide. Due to an incomplete understanding of the factors contributing to disease development, liver transplantation is still the only available cure. A team led by Tim Hendrikx from MedUni Vienna’s Department of Laboratory Medicine has now uncovered a new mechanism that plays […]

January 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

First leukemia patient dosed with SMART101

Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial SloanKettering Cancer Center (MSK). The phaseI/II trial is a multicenter, open-label, first-in-human study expected to enroll up to 36 adult and pediatric patients with hematological malignancies, […]

January 24, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

Onxeo to study prostate cancer drug

FDA clearance for ‘revolutionary’ approach to J-Pouch issue

Orbsen Therapeutics happy with interim diabetic kidney disease study results

New tool to fight antibiotic resistance

Lupus treatment hope from Japanese miRNA research

First patient treated in Atrogi type 2 diabetes clinical study

Sysnav and Roche partner on movement tracking technology

Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product

Milestone for gene-edited therapy for sickle cell disease

Alcohol-related liver disease: mechanism could lead to new therapies

First leukemia patient dosed with SMART101

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!